FB Nasdaq FB Facebook

Biotech Stocks Touching New Highs: Clovis Oncology (NASDAQ:CLVS), Vanda Pharmaceuticals (NASDAQ:VNDA), Insys Therapeutics (NASDAQ:INSY), Albany Molecular Research (NASDAQ:AMRI)

Clovis Oncology Inc. reported a fourth quarter loss of $0.92 per share after the bell Thursday, compared to the loss of $0.81 per share last year. Clovis Oncology Inc. (NASDAQ:CLVS) stock performance was 1.58% in last session and finished the day at $79.62. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 589,825.00 shares. The beta of the stock remained N/A. Clovis Oncology Inc. (NASDAQ:CLVS) insider ownership is 0.60%.

On February 8, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) reported fourth quarter 2013 net loss per share of 23 cents, flat year over year. The reported loss was wider than the Zacks Consensus Estimate of a loss of 18 cents. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) dropped -5.50% to $15.13 yesterday on volume of 0.00 shares. The intra-day range of the stock was $14.95 – $16.55. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has a market capitalization of 503.59 million.

Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products. Insys Therapeutics Inc. (NASDAQ:INSY)’s stock on February 28, 2014 reported a lower of -4.19% to the closing price of $67.28. Its fifty two weeks range is $8.34 – $72.24. The total market capitalization recorded 1.44 billion. The overall volume in the last trading session was 0.00 shares. In its share capital, Insys Therapeutics Inc. (NASDAQ:INSY) has 21.41 million outstanding shares.

FirstLight Fiber, a facilities-based telecommunications service provider operating fiber optic networks in Upstate New York and Northern New England with connectivity to Canada, announced today that Albany. On Friday, shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) dropped -2.92% to close the day at $15.60. Company return on investment (ROI) is 6.20% and its monthly performance is recorded as 45.12%. Albany Molecular Research, Inc. (NASDAQ:AMRI) quarterly revenue growth is 30.33%.